Brokerages Set Henry Schein, Inc. (NASDAQ:HSIC) Price Target at $76.69

Henry Schein, Inc. (NASDAQ:HSIC) has received a consensus rating of “Hold” from the twelve research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $76.4167.

HSIC has been the subject of a number of recent analyst reports. Morgan Stanley upped their price target on shares of Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a research report on Wednesday, November 5th. Evercore ISI upped their target price on shares of Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Wells Fargo & Company raised their price target on Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a report on Wednesday, November 5th. Barclays initiated coverage on Henry Schein in a research note on Monday, December 8th. They issued an “overweight” rating and a $86.00 price objective for the company. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th.

Henry Schein Trading Down 0.9%

NASDAQ:HSIC opened at $76.87 on Wednesday. Henry Schein has a one year low of $60.56 and a one year high of $82.49. The business has a fifty day moving average price of $76.09 and a 200-day moving average price of $70.70. The firm has a market capitalization of $9.05 billion, a price-to-earnings ratio of 24.33, a price-to-earnings-growth ratio of 2.31 and a beta of 0.88. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.40 and a quick ratio of 0.79.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.11. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.The business had revenue of $3.34 billion during the quarter, compared to analyst estimates of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Sell-side analysts forecast that Henry Schein will post 4.74 EPS for the current year.

Hedge Funds Weigh In On Henry Schein

Hedge funds and other institutional investors have recently modified their holdings of the stock. CYBER HORNET ETFs LLC purchased a new position in Henry Schein during the 2nd quarter valued at approximately $25,000. MUFG Securities EMEA plc purchased a new stake in shares of Henry Schein in the second quarter worth approximately $27,000. Flagship Harbor Advisors LLC bought a new stake in shares of Henry Schein during the fourth quarter worth $30,000. ANTIPODES PARTNERS Ltd purchased a new stake in Henry Schein in the 2nd quarter valued at about $43,000. Finally, Steph & Co. purchased a new position in Henry Schein during the 2nd quarter worth $44,000. Institutional investors own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.